

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1681)**

## **VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE PROGRAM UNDER THE REPURCHASE MANDATE**

The board of directors (the “**Board**”) of Consun Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that the Company has decided to implement a share repurchase program (the “**Share Repurchase Program**”) through the exercise of the general mandate to repurchase shares of the Company (the “**Shares**”) that has been granted by the shareholders of the Company (the “**Shareholders**”) to the Board at the annual general meeting held on 31 May 2019 (the “**Repurchase Mandate**”). The Company will repurchase its Shares from the open market.

### **Details of the Share Repurchase Program are as follows:**

Aggregate number of Shares that may be repurchased	:	Up to 45,000,000 Shares (representing approximately 5.16% of the total number of issued Shares of the Company as at 31 May 2019)
Period for the proposed Share repurchase	:	From 6 September 2019 to the conclusion of the next annual general meeting of the Company or revocation or variation of the Repurchase Mandate by the Shareholders in general meeting

Under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the repurchase price of each Share shall not be more than 5% higher than the average closing market price for the Shares over the 5 trading days immediately preceding each repurchase.

The Company intends to finance the repurchase of Shares by its own resources while maintaining sufficient financial resources for the continued growth of its operations.

The Board believes that the current share price of the Company is below its intrinsic value and the value as perceived by investors, it also presents a good opportunity for the Company to repurchase Shares. The Share Repurchase Program reflects the confidence of the Board in the current business development and prospects of the Company. Moreover, the Company believes that actively managing the capital structure and implementing the Share Repurchase Program will optimise the Company’s capital structure, enhance earnings per share and overall shareholder return.

The Share Repurchase Program will be conducted pursuant to the Repurchase Mandate and in compliance with the memorandum of association and the articles of association of the Company, the Listing Rules, The Codes on Takeovers and Mergers and Share Buy-backs (“**Takeovers Code**”) and all other applicable laws and regulations. Shares repurchased (if any) by the Company will be cancelled. The Directors have no intention to exercise the Repurchase Mandate to the extent that would result in the number of Shares in the hands of the public falling below the prescribed minimum percentage as required by the Stock Exchange or give rise to an obligation to make a general offer to the Shareholders under Rules 26 and 32 of the Takeovers Code. Shareholders and potential investors should note that any repurchase of Shares made by the Company under the Share Repurchase Program will be subject to market conditions and will be at absolute discretion of the management of the Company. There is no assurance of the timing, quantity or price of any share repurchases or whether or not the Company will make any repurchases.

**Shareholders and potential investors are advised to exercise cautions when dealing in the shares of the Company**

By order of the Board  
**Consun Pharmaceutical Group Limited**  
**AN Yubao**  
*Chairman*

Hong Kong, 6 September 2019

*As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.*